Integrated Oncology Briefing · Case File OC-2026-0720 · Compiled 20 Jul 2026
Stage II Oral Cavity Cancer,
age 70+ — every credible option, mapped.
A single atlas synthesising Western standard of care, geriatric stratification science, 19 tracked investigational therapies, Eastern and holistic supportive medicine, and Singapore access realities — built for shared decision-making with the care team.
Source tags used throughout → D1 Trials D2 Eastern D3 Geriatric D4 Guidelines D5 Holistic
Section 01 · Pathology & Staging
Know the enemy precisely: what “Stage II” really encodes
Stage II is T2 N0 M0 — a tumour defined not just by surface size but by depth of invasion (DOI), the single metric that drives the decision to treat the clinically silent neck. Tap the anatomy map to explore subsites. D4
≤ 2 cm surface
…with DOI > 5 mm and ≤ 10 mm. A small-looking ulcer that dives deep is still T2 — depth outranks appearance.
2–4 cm surface
…with DOI ≤ 10 mm. Beyond 4 cm or beyond 10 mm depth, the tumour upstages to T3.
The 20% threshold
Once DOI exceeds ~4 mm, the risk of occult nodal micrometastasis passes 20% — the oncologic trigger for treating the N0 neck electively. D4
Schematic — tap a subsite · not to anatomical scale
Oral tongue (mobile, anterior ⅔)
The presumed site for this case. Its dense lymphatic network means depth of invasion — not surface size — drives the elective neck dissection decision. Lateral lesions drain ipsilaterally; lesions near the midline drain bilaterally.
CASE DEFAULT| T1 | T2 (this case) | T3 | |
|---|---|---|---|
| Surface size | ≤ 2 cm | ≤ 2 cm or 2–4 cm | > 4 cm |
| Depth of invasion | ≤ 5 mm | > 5 – ≤ 10 mm | > 10 mm |
| Nodes (this case) | N0 — no clinical/radiological nodal disease; M0 — no distant spread | ||
| Key modifier | DOI ≠ thickness. DOI is measured from the reconstructed basement-membrane baseline, so exophytic (outward-growing) tumours are not artificially upstaged. Extranodal extension (ENE), if ever found in a node, escalates adjuvant therapy to chemoradiation. | ||
High-risk pathological modifiers to request in the report
PNI (perineural invasion) — strong local-recurrence predictor, triggers post-op RT · LVI (lymphovascular invasion) — regional/distant failure signal · WPOI-4/5 (dispersed budding at the invasive front) — aggressive biology · Margin status — the surgeon-controlled prognostic king. D4
Emerging research suggests the minimum safe margin ≈ DOI × 0.5, while the static guideline benchmark stays ≥ 5 mm. Drag the slider:
INVESTIGATIONAL METRIC — NOT YET IN NCCN/ESMO GUIDELINES D4
Section 02 · The Geriatric Lens
Biological age beats chronological age — every time
Roughly 30% of head & neck cancers are diagnosed at 70+, yet older adults make up < 5% of pivotal trial enrolments — so guidelines are extrapolated from younger, fitter cohorts. The fix: structured geriatric assessment before any treatment decision. D1 D4
A score of ≤ 14 flags vulnerability and triggers a full Comprehensive Geriatric Assessment (CGA). Adjust the answers to see classification shift live.
Robust screen. Standard curative-intent therapy should not be withheld on age alone — proceed to full staging and tumour board. D4
| Domain | Tools | What it changes |
|---|---|---|
| Function & mobility | ADL / IADL, Timed-Up-and-Go | Predicts chemo toxicity & post-op stay → triggers pre-surgical physiotherapy (prehab) |
| Nutrition | Mini Nutritional Assessment | > 90% of older HNSCC patients face post-treatment nutritional syndromes → early PEG planning, caloric loading |
| Comorbidity | Charlson Comorbidity Index | CCI ≥ 3 signals high competing health risk → reshapes intensity choices |
| Cognition & mood | MMSE, Geriatric Depression Scale | Determines wound-care / feeding-tube adherence → identifies required caregiver support |
| Polypharmacy | Medication review | Flags interactions with anti-emetics, analgesics — and with cisplatin pathways |
“Fit” vs “Unfit” is destiny
Fit elders tolerated standard platinum regimens with outcomes comparable to younger patients (median OS 14.7 mo in the recurrent/metastatic setting). Unfit patients with ECOG 2 gained zero benefit from intensive therapy and suffered most serious adverse events — the trial arm was stopped for futility. Lesson: de-escalate decisively in frailty. D1 D4
Function outranks tumour stage
Pre-treatment CGA proved that IADL < 8, one-leg stand < 5 s, abnormal MNA and cognitive decline predicted 2-year overall survival more powerfully than age or anatomical stage — independent predictors that should gate every intensity decision. D4
Assessment changes the plan
Universal G8 screening at NCIS/NUH uncovered occult geriatric syndromes in 86% of older adults that routine oncology missed, and modified the cancer plan in 60.7% — while 93% maintained or improved quality of life through coordinated geriatrician-dietitian-rehab care. D4 D5
Section 03 · Western Standard of Care
Surgery first — with four non-negotiable quality numbers
For T2N0M0 oral tongue SCC, all three guideline systems (NCCN v1.2026, ASCO, ESMO/PAGA) converge: primary surgical resection, with radiation reserved for adverse pathology — and definitive RT only for the medically inoperable. D4
Clear margin
The benchmark. Because tongue tissue shrinks ~30% after excision, the surgeon aims for a 10–15 mm gross margin intra-operatively. Close (<5 mm) or positive margins → re-resection if feasible, else PORT. D4
Lymph nodes
ASCO’s quality metric for an adequate elective neck dissection (levels Ia, Ib, II, III). Fewer nodes = suboptimal staging and a lower threshold for adjuvant RT. RT to an undissected neck is not an equivalent substitute. D4
Neck levels cleared
Ipsilateral selective (supraomohyoid) dissection; level IV added on suspicion; bilateral dissection if the tumour approaches the midline — the tongue’s lymphatics cross-talk richly. D4
Free-flap success at 70+
Microvascular reconstruction (radial forearm / ALT flap) viability in older cohorts mirrors younger patients. Hospital stay is longer (~24.6 d), but dietary tolerance, trach weaning and tube independence are comparable with proper prehabilitation. D4
When post-operative radiotherapy (PORT) enters the room
Clear margins + no adverse features = surgery alone is curative. PORT (60–66 Gy to high-risk beds; 50–54 Gy prophylactic, often simultaneous integrated boost) is indicated for: close/positive margins, PNI/LVI, or pathologically positive nodes. Start within 6 weeks of surgery — ESMO is emphatic. D4
| Organ at risk | Constraint | Protects against |
|---|---|---|
| Parotid glands | Mean ≤ 26 Gy | Irreversible xerostomia, dental decay |
| Pharyngeal constrictors | Mean ≤ 50 Gy | Late dysphagia, aspiration risk |
| Spinal cord | Max ≤ 45–50 Gy | Radiation myelopathy |
| Mandible | V60 < 14% | Osteoradionecrosis |
Chemotherapy: a tightly restricted role at 70+
For true Stage II with clear margins, chemotherapy has no role. It enters only with the two highest-risk findings — ENE or positive margins — as concurrent cisplatin with RT (Category 1). The MACH-NC meta-analysis shows the survival advantage of adding chemo to RT disappears past age 70, so the Pan-Asian (PAGA) adaptation explicitly sanctions weekly low-dose cisplatin (40 mg/m²) as a tolerable alternative to 3-weekly 100 mg/m² — reserving high-dose only for the exceptionally fit. D4
| Parameter | NCCN v1.2026 | ASCO (2019, current) | ESMO / Pan-Asian (2020–21) |
|---|---|---|---|
| Primary treatment | Surgery preferred; RT only if inoperable/refusal | Surgery strongly recommended | Surgery strongly recommended |
| cN0 neck | END when DOI > 3–4 mm | END levels Ia/Ib/II/III, ≥ 18 nodes required | END for T2; levels by subsite |
| Clear margin | ≥ 5 mm | ≥ 5 mm | > 5 mm (close = 1–5 mm; positive < 1 mm) |
| Adjuvant chemo trigger | ENE or positive margins | ENE or positive margins (cisplatin 100 mg/m²) | Same; weekly 40 mg/m² accepted; DPD testing not routine in Asians |
| PORT timing | Preferably ≤ 6 wk | ≤ 6 wk | Strongly ≤ 6 wk |
TRACK A · FIT
- Partial glossectomy + ipsilateral END (± free-flap reconstruction)
- Pathology review: margins, DOI, PNI/LVI, nodes, ENE
- Clear + no adverse features → observation
- PNI/LVI / close margin / pN1 → PORT ≤ 6 wk (proton considered)
- ENE or positive margin → CRT; weekly cisplatin if 70+
TRACK B · VULNERABLE
- Prehabilitation 2–4 wk: nutrition loading, physio, med optimisation (MILES/GOLDEN model)
- Re-assess → surgery if reserve improves
- Otherwise definitive RT — hypofractionation considered
- Weekly (not 3-weekly) cisplatin if chemo needed
- Early PEG + speech therapy if swallowing at risk
TRACK C · FRAIL / INOPERABLE
- Organ-preserving track — no aggressive chemo (ELAN-UNFIT lesson)
- PDT if T1/T2 and available (trial setting)
- Or hypofractionated RT (66 Gy / 20 fx model)
- Or EGFR antibody (cetuximab / nimotuzumab) ± RT
- Full supportive-care bundle from day one
5-yr disease-specific survival
74.7–85.1%
in older adults with surgically treated disease; overall survival (57–64%) is pulled lower by competing health conditions, not by the cancer alone. D4
Margins dictate the odds
5–11%
with clear margins vs 10–17% close vs >40% positive (if PORT omitted). Overall early-stage recurrence runs 15–20%, split roughly evenly between local and regional. D4
What the consent form says
~50%
of patients 80+ undergoing major resection + flap experience at least one serious 30-day complication in multi-institutional data; ~11% of previously independent patients needed new ongoing care. CGA-driven selection is the mitigation. D3
Section 04 · The Frontier — Trials & Emerging Therapy
Immunotherapy is moving before the scalpel
The biological rationale: giving checkpoint inhibitors while the tumour and its draining nodes are still intact turns the cancer into its own vaccine — priming T-cells that keep patrolling after resection. Two phase III landmarks now define the space, with a deep pipeline behind them. D1
Phase III · KEYNOTE-689 · FDA-approved perioperatively, June 2025
Perioperative pembrolizumab
Design: 2 cycles neoadjuvant pembrolizumab → surgery → adjuvant pembrolizumab + RT/CRT (up to 15 cycles). 3-yr OS trended favourable (68.4% vs 61.1%). pCR 3%, major pathological response 9.4%.
Phase III · NIVOPOSTOP (GORTEC 2018-01) · 666 patients
Post-operative nivolumab + chemoradiation
High-risk resected disease: standard cisplatin-RT augmented with concurrent + maintenance nivolumab. Benefit driven by locoregional control. An ASCO 2026 post-hoc analysis settled a key fear: extensive neck dissection (>39 nodes) does not blunt immunotherapy efficacy.
Section 05 · De-escalation & Organ Preservation
Doing less, precisely — the highest-value science for the 70+
Two goals that sound paradoxical: maximise oncologic control and minimise surgical/radiation morbidity. For an older patient, preserving shoulder function, speech and swallowing is the outcome that defines independence. D1
Spare 78% of patients a full neck dissection
Radiotracer (⁹⁹ᵐTc-nanocolloid / tilmanocept) + SPECT/CT maps the first 1–3 draining “sentinel” nodes. If ultrastaging is negative, the rest of the neck is spared — avoiding spinal accessory nerve traction, chronic shoulder pain and lost range of motion that erode independent living.
DIAGNOSTIC ACCURACY
NEGATIVE PREDICTIVE VALUE
DOI FALSE-NEGATIVE RISK LINE
False-negative risk rises with DOI > 6 mm or tumour > 25 mm. Landmark trials: NRG-HN006 (SLNB vs END, endpoint = patient-reported neck/shoulder function) and PRECEDENT (SLNB mapping to personalise — and shrink — neck radiation fields). D1
If neoadjuvant therapy erases the tumour, can RT be skipped?
20–30% of patients achieve a pathological complete response after neoadjuvant immunochemotherapy. Current guidelines still mandate 60–66 Gy based on pre-treatment stage — but high-dose RT carries lifelong xerostomia, trismus, dysphagia and osteoradionecrosis risk that hits the elderly hardest. The evidence is split:
Verdict: investigational — omission belongs in trials with biomarker stratification. D1
Light-activated tumour destruction, anatomy fully preserved
An IV photosensitiser accumulates in tumour; a fibre-optic laser at a specific wavelength triggers reactive-oxygen destruction of cancer cells and tumour vasculature — while the connective-tissue scaffold, muscle and nerves survive. Outpatient, no general anaesthesia, repeatable, and it never burns bridges to later surgery or RT.
In trial now: Roswell Park’s phase II RCT (NCT02119728) randomises T1/T2 oral cavity SCC to surgery vs PDT with second-generation HPPH — skin photosensitivity down from months to 7–14 days. Preclinical frontier: porphysome nanoparticles show 6–40× selective tumour uptake and 100% complete ablation in orthotopic rabbit models with flawless cosmetic healing. D1
The Bragg Peak spares what matters
Pencil-beam-scanning protons deposit maximum energy inside the target and stop — virtually zero exit dose to salivary glands, constrictors and mandible. Phase III data from MD Anderson: equivalent progression-free survival vs IMRT with significantly less malnutrition, dry mouth and feeding-tube dependence. For a 70+ patient, avoiding a permanent feeding tube is a monumental preservation of independence. Available in Singapore (Singapore Advanced Medicine). D1
Section 06 · Eastern Medicine — A Critical Evaluation
The evidence line: supportive, yes — curative, no
Traditional Chinese Medicine, Japanese Kampo and Ayurveda have validated, guideline-endorsed roles in toxicity management — and zero phase III evidence of tumour-directed effect. The discipline is keeping those two facts strictly separated. D2
🪡 Acupuncture for radiation-induced xerostomia — ASCO/SIO recommended D2
ARIX RCT (UK, n=145): significant relief of severe dry mouth (OR 2.01), sticky saliva (OR 1.67) and night waking for fluids (OR 1.71) — with no change in measured salivary flow. The benefit is real but neuromodulatory/subjective.
MD Anderson × Fudan phase III (n=339): true acupuncture cut clinically significant xerostomia to 34.6% vs 55.1% standard care at 1 year (XQ score 26.6 vs 34.8, p=0.001). Fascinating wrinkle: Shanghai patients showed almost no placebo response to sham needling; US patients showed a massive one — culture shapes symptom reporting.
Bottom line: joint ASCO/SIO guidelines give acupuncture a moderate-strength recommendation for head & neck xerostomia — the only Eastern modality at that level.
🇯🇵 Hangeshashinto (TJ-14, Kampo) — shortens severe mucositis D2
Seven-herb formula that inhibits COX-2/PGE2 in oral keratinocytes and promotes tissue repair via the CXCL12/ERK pathway. Used as a 30-second rinse-and-spit.
HNSCC double-blind RCT: median duration of severe mucositis 3.7 → 1.3 days. Larger colorectal RCT: grade ≥2 duration 10.5 → 5.5 days (p=0.018). Meta-analysis: marginal prevention (RR 0.86, p=0.05) — it accelerates healing rather than preventing onset.
🟡 Topical curcumin — the bioavailability “flaw” becomes a safety feature D2
Curcumin potently inhibits NF-κB, the amplifier of the mucositis inflammatory cascade. Meta-analyses of 20+ RCTs: topical mouthwash/gel reduces WHO mucositis grades, delays ulceration onset and cuts VAS pain scores vs chlorhexidine or placebo.
Its notorious poor systemic absorption — usually a drug-development problem — here concentrates the anti-inflammatory exactly at the injured mucosa with no systemic pharmacokinetic interference with circulating chemotherapy. That is the template for safe botanical use during treatment: topical, non-absorbed, local.
🌿 Ayurvedic & TCM rinses — delaying and softening mucositis D2
Draksha Guduchyadi Kashaya (therapeutic gargle, RCT n=70): delayed mucositis onset (p=0.049) and reduced pharyngitis/laryngitis vs soda-salt rinses. Yashtimadhu (licorice) pilot: grade 3 mucositis 15.5% vs ~43% conventional. Triphala + povidone-iodine: delayed onset, less weight loss, no compromise of tumour response.
TCM (Taiwan NHIRD, 561 users vs 2,395 non-users): Chinese herbal medicine users had lower risk of severe mucositis (aHR 0.68); formulas like Gan-Lu-Yin and Sha Shen Mai Dong Tang associate with modest salivary and QoL gains post-RT. Retrospective — confounding likely — but directionally consistent.
🔬 The curative-claim reality check — in vitro ≠ in vivo D2
Formulas like San-Zhong-Kui-Jian-Tang and botanicals (neem, saffron, ginger) show genuine OSCC-cell cytotoxicity in petri dishes via MAPK/EMT modulation. The fallacy: achieving those effects requires 108–217 mg/ml concentrations that are pharmacologically unreachable in human plasma — poor gut absorption, first-pass metabolism, rapid renal clearance.
Retrospective “TCM users live longer” data are warped by immortal-time bias (you must survive long enough to become a long-term TCM user) and healthy-user bias (higher health literacy, better nutrition, superior adherence). There is no phase III placebo-controlled evidence that any TCM, Kampo or Ayurvedic formula acts as a standalone antineoplastic in HNSCC. Singapore’s HSA legally prohibits traditional medicines from claiming to prevent, alleviate or cure cancer.
The Safety Cabinet · Non-negotiable interactions
Three ways “natural” can sabotage curative treatment
Every item below is documented in the dossiers. The rule that emerges: topical rinses are safe; systemic botanicals during active RT/chemo are not. D2 D5
Antioxidants shield the tumour, not just you
Radiation works by generating free radicals that shatter tumour DNA. High-dose systemic antioxidants (vitamin E, β-carotene, concentrated extracts) scavenge those radicals — protecting cancer cells too. The Bairati/Meyer RCT (n=540) gave vitamin E + β-carotene during curative RT: mucositis dropped, but overall survival worsened (HR 1.38), recurrence rose (HR 1.37) and second primaries spiked (HR 2.88). ASCO/ASTRO advise avoiding antioxidant supplements during and right after RT. Get antioxidants from whole foods instead.
Herbs rewrite cisplatin’s pharmacokinetics
Echinacea modulates CYP3A4 and P-glycoprotein — case-reported precipitous, transfusion-requiring myelosuppression with cisplatin/etoposide. Triphala inhibits CYP2E1, unpredictably altering cisplatin clearance. Reverse direction too: cisplatin eradicates the gut flora that ginsenoside Rb1 needs — the chemotherapy silently nullifies the herb.
How to use Eastern medicine safely
MSKCC’s “About Herbs” database screens CYP450 interactions worldwide. Singapore’s NCCS runs an integrative oncology “sandbox” — supervised, evidence-based TCM/acupuncture under the primary oncology team. MASCC/ISOO stay conservative on unstandardised botanicals but endorse acupuncture for xerostomia. Declare every supplement at every visit.
| Botanical / supplement | Concurrent therapy | Mechanism | Consequence |
|---|---|---|---|
| High-dose antioxidants (Vit E, β-carotene) | Radiotherapy | Scavenges RT-generated ROS — systemic radioprotection of tumour | High risk: reduced tumour control, higher recurrence, worse overall survival |
| Echinacea | Cisplatin / etoposide | CYP3A4 + P-gp modulation | High risk: chemo accumulation → severe myelosuppression |
| Triphala (systemic) | Cisplatin | CYP2E1 inhibition | Unknown/risk: unpredictable platinum clearance |
| Ginseng (Rb1) | Cisplatin | Gut flora eradicated by chemo | Herbal effect fully lost |
| Topical curcumin / TJ-14 gargles | Chemoradiation | Local COX-2 / NF-κB inhibition, negligible absorption | Safe: no systemic interference |
Section 07 · Holistic & Supportive Oncology
Build the host’s reserve before the storm arrives
Prehabilitation, clinical nutrition, exercise oncology, mind-body therapy and sleep medicine are not “alternative” — they are the evidence-based infrastructure that lets a 70+ body tolerate curative treatment and reclaim function afterwards. D5
Expand the physiological runway
Multimodal programs (aerobic + resistance + nutrition + psychoeducation) cut serious post-operative complications (Clavien-Dindo ≥ III), shorten stay by ~4 days, and a meta-analysis shows a 38% reduction in serious-outcome risk when exercise pairs with nutritional support. 6-minute-walk distances improve measurably in 2–5 pre-op weeks. D5
Mendelsohn + effortful swallows
10 repetitions, 3× daily during RT — begun while tissues are still pliable — preserves the swallowing reflex and cuts severe late dysphagia. Nutrition-based approaches alone fail to prevent mechanical degradation; exercise-based ones succeed. D5
60–88% present or become malnourished
Screen at diagnosis (MUST). Targets: 30–35 kcal/kg/day, protein up to 2 g/kg/day. C3-vertebra MRI now detects silent sarcopenia early. If oral intake falls <50% of needs → prophylactic PEG. Tactics: cold/odourless foods for nausea, gravies and oils for lubrication, small frequent meals at peak energy. Immunonutrition (arginine, glutamine, ω-3) peri-operatively reduces surgical-site infections and shortens stay. D5
| Pattern | Evidence | Verdict |
|---|---|---|
| Mediterranean | Pooled RR 0.96 for overall outcomes; HR 0.92 head & neck; pre-diagnosis adherence OR 0.561; 15% lower 5-yr risk for oral cavity tumours. Polyphenols + fibre → short-chain fatty acids → immunomodulation. | ✅ Highly recommended |
| Ketogenic | MIT 2026: glucose deprivation upregulates BACH1, fuelling intestinal tumour growth and increasing metastasis in models; plus fibre/micronutrient restriction and lean-mass wasting. | ❌ Strongly discouraged |
| Alkaline | Blood pH is physiologically buffered — diet cannot alter it. Delivers protein-calorie malnutrition with zero upside. | ❌ Contraindicated |
| Gerson therapy | Raw-juice extremes + coffee enemas: electrolyte derangement, infection and bowel-perforation risk; no efficacy signal. | ❌ Contraindicated |
The mucositis & dysgeusia toolkit (MASCC/ISOO-aligned)
• Photobiomodulation (low-level laser): recommended for prevention/treatment — modulates cytokines, accelerates epithelial repair.
• Benzydamine rinse: recommended for moderate-dose RT (≤50 Gy) without chemo.
• Polaprezinc (zinc + L-carnosine chelate): reduces grade 3/4 mucositis, pain, analgesic need and weight loss without blunting tumour response — and outperforms plain zinc sulfate for taste recovery.
• Pure honey: severity RR 0.22; grade 3–4 rates 75% → 20% in trials; cheap, safe, effective.
• L-glutamine: mixed evidence — MASCC only “suggests with caution”; benefit mainly opioid-sparing.
⚠ Long-term zinc supplementation causes copper deficiency (anaemia, neutropenia, irreversible gait neuropathy) — short courses only. D5
Exercise oncology — ASCO 2022 guideline: prescribe it
Supervised aerobic + resistance training during curative treatment reduces cancer-related fatigue (SMD −0.52), anxiety and depression; preserves VO₂ max and lean mass — the pharmacokinetic buffer against dose-limiting chemo toxicity. In patients 70+, tailored HIIT produced a 135% endurance gain and 51% fewer 30-day post-op complications; prehab has converted previously ineligible frail patients into treatment candidates. Epidemiology links high activity with 24–31% lower cancer-specific risk ratios — though ASCO notes RCT survival evidence is still maturing. D5 D3
8 weeks that rewire the trauma response
Mindfulness-Based Stress Reduction produces large, durable reductions in depression, anxiety and internalised stigma (disfigurement, speech change) in head & neck patients, with gains in hope, post-traumatic growth and pain perception. D5
Fix the architecture, skip the sedatives
Cognitive-behavioural therapy for insomnia beats acupuncture for moderate–severe disease (ISI −10.9 vs −8.3) with durable effects. Melatonin is the safe pharmacologic adjunct — short half-life, no hangover, under trial investigation for immunomodulatory adjunct effects. Avoid chronic benzodiazepines. D5
New Voice Club (Singapore Cancer Society)
Peer rehabilitation where survivors master artificial larynx, oesophageal and tracheo-oesophageal speech — collapsing isolation and restoring communicative confidence alongside clinical speech therapy at SGH. D5
Section 08 · Geographic Accessibility — Singapore
World-class infrastructure, with a cost-effectiveness gatekeeper
Singapore anchors an advanced oncology research ecosystem — but access to newly approved agents runs through the MOH Drug Advisory Committee and the Cancer Drug List. Trials are often the pragmatic doorway. D1
The institutional map
• National Cancer Centre Singapore (NCCS): Clinical Trials Operations managing hundreds of protocols incl. early-phase basket trials; geriatric oncology service; integrative oncology “sandbox”; head & neck surgery department.
• NCIS / NUH: the GOLDEN programme — universal G8 screening, CGA, MILES surgical prehab (protein loading + targeted exercise to reverse sarcopenia), hybrid telemedicine follow-up.
• Singapore Translational Cancer Consortium (STCC): streamlines cross-cluster trial enrolment.
• Singapore Advanced Medicine: pencil-beam-scanning proton therapy (Bragg Peak dosimetry). D1 D4
Locally pioneered science to watch
• Exosome isoform D82: NCCS discovered only 3–5% of HNSCC patients respond to EGFR inhibitors; engineering human-grade exosomes carrying isoform D resensitised resistant tumours in lab models — now scaling with the Bioprocessing Technology Institute toward first-in-human trials.
• Nimotuzumab programme: NCCS-led phase II/III trials (NCT00702481, NCT00957086) adding this humanised EGFR antibody to chemoradiation — rarely causes the severe rash or low magnesium of cetuximab, making it notably elderly-friendly.
• ADIVO (ADG106 + nivolumab) and REMAIN (relatlimab + immunotherapy) — active Singapore enrolment. D1
Section 09 · Simulation 2 — The Pathway Builder
Proposed treatment pathways, generated live
Set the patient’s physiological profile and priorities — the builder assembles a four-phase plan from the exact evidence in these dossiers, plus matched investigational options. Presets load three archetypes instantly. Educational tool — the multidisciplinary tumour board makes the real decision.
Patient parameters
The 12 questions that protect a 70+ patient
Section 10 · Source Atlas — Where every claim comes from
378 cited sources across five research dossiers
Peer-reviewed journals, phase III trials, conference abstracts (ASCO 2025–26), regulatory filings, national registries and preclinical pipelines. Every tag in this atlas (D1–D5) traces back to the dossier below.
Oral Cavity SCC — Clinical Trials Landscape
Global + Singapore analysis of investigational therapeutics: KEYNOTE-689, NIVOPOSTOP, ficerafusp alfa, SLNB trials, PDT, proton therapy, HSA/CDL access economics.
NEJM · JCO · FDA · ClinicalTrials.gov · ASCO Post · PMC
Eastern Medicine — Critical Evaluation
Acupuncture, Kampo TJ-14, Ayurvedic and TCM rinses; herb–drug interaction pharmacology (CYP450/P-gp); antioxidant paradox; HSA & MASCC/ISOO governance.
PubMed · MASCC/ISOO · ASCO/SIO · HSA Singapore
Deep Research — Geriatric Assessment & Decision Support
GA endorsement (ASCO/SIOG/NCCN), de-intensification evidence in elderly, surgical/RT morbidity data, second opinions, tumour boards, patient decision aids.
ASCO · SIOG · NCCN · Roswell Park · registry cohorts
Elderly Oral Cancer — Treatment Guidelines Synthesis
AJCC 8th→v9 staging, NCCN v1.2026 vs ASCO vs ESMO/PAGA, surgical quality metrics, PORT/CRT thresholds, G8/CGA tools, ELAN/EGeSOR/GOLDEN programmes, outcomes data.
NCCN · ASCO · ESMO/PAGA · AJCC · SIOG · Singapore GOLDEN
Holistic & Supportive Interventions
Prehabilitation, clinical nutrition, dietary patterns (incl. MIT ketogenic findings), mucositis/dysgeusia toolkit, exercise oncology, MBSR, CBT-I, sleep & community rehab.
MASCC/ISOO · ASCO 2022 · ESPEN · MIT/Columbia preclinical
EVIDENCE MIX: PHASE III RCTS · PHASE II TRIALS · CONFERENCE ABSTRACTS (ASCO 2025–26) · META-ANALYSES · RETROSPECTIVE REGISTRIES · PRECLINICAL MODELS · REGULATORY DOCUMENTS · GUIDELINE SYSTEMS. UNPUBLISHED/EARLY-STAGE PIPELINES ARE EXPLICITLY LABELLED “PRECLINICAL” OR “INVESTIGATIONAL” WHEREVER THEY APPEAR.